Intellia pauses gene therapy trials after patient suffers liver injury, shares slide

(Reuters) -Intellia Therapeutics has temporarily stopped dosing and patient screening in two late-stage studies of its gene therapy after a participant developed serious liver injury, the company said on Monday, sending its shares down over 46% in morning trading. The patient, who received Nexiguran ziclumeran (nex-z), showed sharp spikes in liver enzymes and elevated bilirubin, triggering a protocol-defined safety pause, the company said.